Paxlovid (nirmatrelvir-ritonavir) is efficient at stopping hospitalization and dying from COVID-19, however few folks use it. A paper by SteelFisher et al. (2024) surveyed 1,430 American adults to search out out why. Their survey revealed sufferers had a lack of understanding of the therapy in addition to misinformation in regards to the therapy (amongst those that have been conscious of it). Particularly:
A majority of respondents (85 %) had no or low consciousness of Paxlovid, together with 31 % who had by no means heard of it. Even amongst those that have been conscious of the drug, many held misperceptions about its effectiveness (39 %), adversarial results (86 %), and requisite timing (61 %) that would result in underuse. Decrease consciousness and misperceptions have been extra widespread amongst medically susceptible and deprived populations who would possibly profit most from Paxlovid entry, together with adults unvaccinated towards COVID-19, these with decrease ranges of schooling, and Black and Hispanic or Latino adults.
You possibly can learn the complete paper right here.
